Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke.
Stroke is a common and often fatal event, and, in survivors, it is accompanied by a high risk of recurrence. Ischemic stroke is associated with abnormal platelet activity and thrombus formation. In addition to their roles in the development of acute thrombi, platelets serve as a bridge for leukocytes within the vasculature. Myeloid leukocytes are critical mediators of atherosclerosis and atherothrombosis. Interactions between platelets and leukocytes foster an inflammatory and thrombotic milieu that influences lesion progression, facilitates plaque rupture, and triggers thrombus formation and embolization. Accordingly, antiplatelet agents, including aspirin, dipyridamole, and clopidogrel, are recommended therapies for most patients with a history of stroke. In addition to mitigating thrombosis, antiplatelet drugs have direct and indirect effects on inflammation, which may translate to enhanced clinical efficacy.
Program in Molecular Medicine, University of Utah, Salt Lake City, Utah, USA.
Zechariah G
ZG
Franks
Robert A
RA
Campbell
Andrew S
AS
Weyrich
Matthew T
MT
Rondina
D000818:Animals; D001792:Blood Platelets / Q000502:physiology; D002545:Brain Ischemia / Q000097:blood / Q000188:drug therapy; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000188:drug therapy; D007962:Leukocytes / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D020521:Stroke / Q000097:blood* / Q000188:drug therapy; D013923:Thromboembolism / Q000097:blood* / Q000188:drug therapy
D010975:Platelet Aggregation Inhibitors